---
noindex: true
sitemap: false
layout: default
title: Aclidinium Bromide
parent: AI Predictions (L5)
nav_order: 22
evidence_level: L5
indication_count: 0
last_modified_at: 2026-11-12
predicted_indications: []
---

# Aclidinium Bromide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Aclidinium Bromide: Evidence Pack Incomplete — No Repurposing Predictions Available
{: .text-alpha }

## One-Sentence Summary

Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) used for COPD maintenance therapy.
This Evidence Pack contains **no TxGNN repurposing predictions** and has critical data gaps across safety, mechanism of action, and original indication fields.
A full repurposing evaluation cannot be completed until these gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only, but no predictions were returned |
| EU Market Status | Marketed (valid licences: 4 of 4) |
| Number of Authorizations | 4 (valid: 4) |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the SmPC for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The `predicted_indications` array is empty, meaning TxGNN returned no repurposing candidates for aclidinium bromide in this run. Combined with blocking data gaps in safety and MOA data, there is no actionable prediction to evaluate.

**To proceed, the following is needed:**

- **Re-run TxGNN prediction** — the `predicted_indications` array is empty; confirm whether the drug was correctly matched to a DrugBank ID before re-running (DrugBank ID is currently null)
- **Resolve DG001 (Blocking)** — obtain safety warnings and contraindications from the drug label to enable safety screening
- **Resolve DG002 (High)** — retrieve mechanism of action from DrugBank to support mechanistic plausibility analysis
- **Confirm market status** — aclidinium bromide is known to be authorized in multiple markets (e.g., Eklira Genuair in the EU)

<!-- review:begin eu-lic-20261106-aclidinium_bromide-1 -->

> **Review correction (2026-11-06)**: Originally stated: "**Confirm market status** — aclidinium bromide is known to be authorized in multiple markets (e.g., Eklira Genuair in the EU); zero authorizations on record suggests a data ingestion issue that should be investigated before proceeding" Removed: it conflicted with the EMA data (the EMA medicines data as of 2026-11-06). The EMA data list 4 EU marketing authorisations for this drug, 4 current; the Quick Overview and the table under EU Market Information show the current figures. Source: [EMA – Medicines (centrally authorised)](https://www.ema.europa.eu/en/medicines).

<!-- review:end eu-lic-20261106-aclidinium_bromide-1 -->

<!-- review:begin log -->

## Review Log

Below is the review log for this page: statements checked against official European Medicines Agency data (centrally authorised medicines). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.

| Review date | Item | Action | Source |
|------|------|------|------|
| 2026-11-06 | Removed: "zero authorizations on record suggests a data ingestion issue that should be investigated before proceeding" | Corrected | [EMA – Medicines (centrally authorised)](https://www.ema.europa.eu/en/medicines) |

<!-- review:end log -->

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

